# Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)

> **NCT06683755** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 30 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Relatlimab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT06683755
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2030-08-16
- **Final completion:** 2032-08-16
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06683755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06683755, "Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06683755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*